Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Devices as destination therapy.

Eugene L Kukuy1, Mehmet C Oz, Eric A Rose

  • 1Columbia University-New York Hospital, New York, NY 10032, USA.

Cardiology Clinics
|June 7, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

External Support for Saphenous Vein Grafts in Coronary Artery Bypass Surgery: A Randomized Clinical Trial.

JAMA cardiology·2022
Same author

Rationale and design of a randomized trial evaluating an external support device for saphenous vein coronary grafts.

American heart journal·2021
Same author

Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation.

The New England journal of medicine·2021
Same author

Association of Clinical Outcomes With Left Ventricular Assist Device Use by Bridge to Transplant or Destination Therapy Intent: The Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) Randomized Clinical Trial.

JAMA cardiology·2020
Same author

Discontinuing amiodarone treatment prior to heart transplantation lowers incidence of severe primary graft dysfunction.

Clinical transplantation·2020
Same author

Impairment of Myocardial Glutamine Homeostasis Induced By Suppression of the Amino Acid Carrier SLC1A5 in Failing Myocardium.

Circulation. Heart failure·2019
Same journal

At the Edge of the Possible: A New Standard for Cardiovascular Critical Care.

Cardiology clinics·2026
Same journal

End-of-Life Care in the Cardiovascular Intensive Care Unit.

Cardiology clinics·2026
Same journal

Strategies to Reduce Failure to Rescue after Cardiac Surgery.

Cardiology clinics·2026
Same journal

Embracing Enhanced Recovery After Cardiac Surgery Program.

Cardiology clinics·2026
Same journal

Post-Heart Transplantation Intensive Care Unit Recovery: A Phase-Based Approach.

Cardiology clinics·2026
Same journal

A Practical Guide to Intensive Care Unit Management after Left Ventricular Assist Device Implantation.

Cardiology clinics·2026
See all related articles

Destination therapy using mechanical circulatory support aims to improve end-stage heart failure treatment. Newer magnetic levitation pumps offer enhanced reliability, reduced size, and lower cost for better patient quality of life.

Area of Science:

  • Cardiovascular Medicine and Medical Devices
  • Biomedical Engineering

Background:

  • End-stage heart failure management has long sought effective destination therapy.
  • Mechanical circulatory support devices are evolving to meet this need.

Purpose of the Study:

  • To evaluate the potential of advanced circulatory support systems as destination therapy for heart failure.
  • To highlight the benefits of emerging pump technologies in improving patient outcomes and quality of life.

Main Methods:

  • Review of current and emerging mechanical circulatory support technologies.
  • Focus on centrifugal pumps utilizing Magnetic Levitation (Maglev) technology.
  • Consideration of design modifications addressing reliability, size, and cost.

Main Results:

Related Experiment Videos

  • Newer centrifugal pumps based on Maglev technology demonstrate potential for increased reliability and durability.
  • Maglev systems offer frictionless pumping, reduced thrombogenicity, and minimal noise.
  • These advancements aim to improve the quality of life for patients requiring mechanical circulatory assistance.

Conclusions:

  • Continued research and federal support are crucial for the widespread adoption of circulatory assistance as destination therapy.
  • Future devices must balance technological improvement with cost-effectiveness compared to the native heart.
  • Emerging Maglev pump technology shows promise for more effective and durable long-term heart failure management.